<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <title>Optic Neuritis in Multiple Sclerosis - 50 Slides</title>
    <!-- Reveal.js Core CSS -->
    <link
      rel="stylesheet"
      href="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/reveal.css"
    />
    <!-- Reveal.js Theme (choose one of the themes in /dist/theme) -->
    <link
      rel="stylesheet"
      href="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/theme/black.css"
      id="theme"
    />
    <style>
      /* Optional custom styling */
      .reveal section h2 {
        margin-bottom: 0.5em;
      }
      .reveal section ul {
        margin-top: 0.5em;
      }
    </style>
  </head>
  <body>
    <div class="reveal">
      <div class="slides">
        <!-- Slide 1 -->
        <section>
          <h2>Slide 1: Title Slide</h2>
          <ul>
            <li>
              <strong>Title:</strong> Optic Neuritis in Multiple Sclerosis
            </li>
            <li>
              <strong>Subtitle:</strong> A Comprehensive Review (History, Exam,
              Diagnosis, Management)
            </li>
            <li><strong>Presenter:</strong> [Your Name]</li>
            <li><strong>Date:</strong> [Optional]</li>
          </ul>
        </section>

        <!-- Slide 2 -->
        <section>
          <h2>Slide 2: Outline</h2>
          <ol>
            <li>Introduction</li>
            <li>Epidemiology &amp; Risk Factors</li>
            <li>Pathophysiology</li>
            <li>Types of Optic Neuritis</li>
            <li>Relationship Between ON and MS</li>
            <li>Clinical Features</li>
            <li>History Taking</li>
            <li>Clinical Examination</li>
            <li>Investigations</li>
            <li>Differential Diagnosis</li>
            <li>Management</li>
            <li>Prognosis &amp; Follow-Up</li>
            <li>Special Considerations &amp; Future Directions</li>
            <li>Conclusion</li>
            <li>References</li>
          </ol>
        </section>

        <!-- Slide 3 -->
        <section>
          <h2>Slide 3: Definition of Optic Neuritis</h2>
          <ul>
            <li>
              <strong>Optic Neuritis (ON)</strong>: Inflammatory demyelination
              of the optic nerve.
            </li>
            <li>
              <strong>Common Presentation</strong>: Subacute onset of unilateral
              vision loss and eye pain.
            </li>
            <li>
              <strong>Significance</strong>: Frequently the initial
              manifestation of MS.
            </li>
          </ul>
        </section>

        <!-- Slide 4 -->
        <section>
          <h2>Slide 4: Importance of Studying ON in MS</h2>
          <ul>
            <li>
              ON is often the <strong>first demyelinating event</strong> in MS.
            </li>
            <li>~15–20% of MS patients initially present with ON.</li>
            <li>
              Provides insight into <strong>autoimmune demyelination</strong> in
              the CNS.
            </li>
            <li>Early detection can prompt disease-modifying therapies.</li>
          </ul>
        </section>

        <!-- Slide 5 -->
        <section>
          <h2>Slide 5: Epidemiology</h2>
          <ul>
            <li><strong>Age:</strong> Common in young adults (20–40 years).</li>
            <li><strong>Gender:</strong> Female predominance (~3:1).</li>
            <li>
              <strong>Geographic Variation:</strong> Higher incidence further
              from the equator.
            </li>
            <li>
              <strong>Association:</strong> ~50% of isolated ON patients develop
              MS within 15 years.
            </li>
          </ul>
        </section>

        <!-- Slide 6 -->
        <section>
          <h2>Slide 6: Risk Factors</h2>
          <ul>
            <li>
              <strong>Genetic Predisposition</strong>: Certain HLA genotypes.
            </li>
            <li>
              <strong>Environmental Factors</strong>:
              <ul>
                <li>Low Vitamin D</li>
                <li>Smoking</li>
                <li>Viral triggers (EBV association)</li>
              </ul>
            </li>
            <li>
              <strong>Autoimmune Disorders</strong>: Additional autoimmune
              diseases may predispose to ON.
            </li>
          </ul>
        </section>

        <!-- Slide 7 -->
        <section>
          <h2>Slide 7: Basic Immunopathology</h2>
          <ul>
            <li>
              <strong>Autoimmune Attack</strong>: T-cells, B-cells, and
              antibodies target myelin.
            </li>
            <li>
              <strong>Key Immune Cells:</strong> T lymphocytes (CD4+, CD8+), B
              cells, macrophages.
            </li>
            <li>
              <strong>Inflammatory Cascade</strong>: Cytokines (IL-2, IFN-γ)
              perpetuate demyelination and axonal injury.
            </li>
          </ul>
        </section>

        <!-- Slide 8 -->
        <section>
          <h2>Slide 8: Demyelination in the Optic Nerve</h2>
          <ul>
            <li>
              <strong>Myelin Sheath Destruction</strong>: Slows nerve
              conduction.
            </li>
            <li>
              <strong>Axonal Injury</strong>: Potential for permanent damage.
            </li>
            <li>
              <strong>Remyelination</strong>: Explains partial or full visual
              recovery.
            </li>
          </ul>
        </section>

        <!-- Slide 9 -->
        <section>
          <h2>Slide 9: Role of MS Plaques</h2>
          <ul>
            <li>
              <strong>MS Plaques</strong>: Focal areas of CNS demyelination.
            </li>
            <li>
              <strong>Location</strong>: Periventricular, juxtacortical,
              infratentorial, spinal cord.
            </li>
            <li>
              <strong>MRI Correlation</strong>: T2/FLAIR hyperintensities;
              active lesions enhance with gadolinium.
            </li>
            <li>
              <strong>Optic Nerve Lesions</strong>: Enhancement indicates acute
              inflammation in ON.
            </li>
          </ul>
        </section>

        <!-- Slide 10 -->
        <section>
          <h2>Slide 10: Typical vs. Atypical ON</h2>
          <ul>
            <li>
              <strong>Typical ON (Demyelinating)</strong>:
              <ul>
                <li>Associated with MS</li>
                <li>Unilateral, painful, better recovery</li>
                <li>MRI often shows MS-like lesions</li>
              </ul>
            </li>
            <li>
              <strong>Atypical ON</strong>:
              <ul>
                <li>Causes: NMO, MOG disease, infections, sarcoidosis</li>
                <li>Often bilateral or severe, can have worse prognosis</li>
              </ul>
            </li>
          </ul>
        </section>

        <!-- Slide 11 -->
        <section>
          <h2>Slide 11: Clinical Clues to Atypical ON</h2>
          <ul>
            <li>Poor response to steroids</li>
            <li>Recurrent bilateral involvement</li>
            <li>Severe vision loss at onset</li>
            <li>Systemic symptoms (e.g., rash, arthralgias)</li>
            <li>Marked disc swelling on imaging</li>
          </ul>
        </section>

        <!-- Slide 12 -->
        <section>
          <h2>Slide 12: ON as an Early Indicator of MS</h2>
          <ul>
            <li>First symptom in 15–20% of MS patients</li>
            <li>~50% develop MS within 15 years after first ON</li>
            <li>MRI brain lesions = higher MS conversion risk</li>
          </ul>
        </section>

        <!-- Slide 13 -->
        <section>
          <h2>Slide 13: MS Diagnostic Criteria (Brief)</h2>
          <ul>
            <li>
              <strong>McDonald Criteria</strong>: Dissemination in time &amp;
              space
            </li>
            <li>
              <strong>Clinical Attacks + MRI Evidence</strong>:
              <ul>
                <li>Dissemination in Space: ≥2 CNS regions</li>
                <li>Dissemination in Time: Lesions at different times</li>
              </ul>
            </li>
            <li>Optic Neuritis helps fulfill clinical criteria</li>
          </ul>
        </section>

        <!-- Slide 14 -->
        <section>
          <h2>Slide 14: Vision Loss</h2>
          <ul>
            <li>
              <strong>Nature</strong>: Sudden or subacute onset over days to 1-2
              weeks
            </li>
            <li>
              <strong>Severity</strong>: Ranges from mild blurring to complete
              vision loss
            </li>
            <li>
              <strong>Laterality</strong>: Usually unilateral in demyelinating
              ON
            </li>
            <li>
              <strong>Progression</strong>: Worsens ~1 week, then
              stabilizes/improves
            </li>
          </ul>
        </section>

        <!-- Slide 15 -->
        <section>
          <h2>Slide 15: Pain with Eye Movement</h2>
          <ul>
            <li>Occurs in ~90% of ON patients</li>
            <li>Retro-orbital pain worsened by eye movement</li>
            <li>Due to inflammation of optic nerve sheath</li>
          </ul>
        </section>

        <!-- Slide 16 -->
        <section>
          <h2>Slide 16: Color Vision Defects</h2>
          <ul>
            <li>Red desaturation is a hallmark</li>
            <li>Ishihara plates may show color discrimination deficits</li>
            <li>Persisting color vision changes even after VA improves</li>
          </ul>
        </section>

        <!-- Slide 17 -->
        <section>
          <h2>Slide 17: Visual Field Defects</h2>
          <ul>
            <li>Central or cecocentral scotoma most common</li>
            <li>Diffuse field loss or altitudinal defect (less common)</li>
            <li>
              Confrontation testing (basic), automated perimetry (detailed)
            </li>
          </ul>
        </section>

        <!-- Slide 18 -->
        <section>
          <h2>Slide 18: Uhthoff’s Phenomenon</h2>
          <ul>
            <li>Worsening of neuro symptoms with heat/exercise</li>
            <li>
              Elevated temperature impairs conduction in demyelinated fibers
            </li>
            <li>May transiently reduce visual acuity</li>
          </ul>
        </section>

        <!-- Slide 19 -->
        <section>
          <h2>Slide 19: Relative Afferent Pupillary Defect (RAPD)</h2>
          <ul>
            <li>Checked via the swinging flashlight test</li>
            <li>Indicates unilateral/asymmetric optic nerve dysfunction</li>
            <li>More pronounced = more severe ON involvement</li>
          </ul>
        </section>

        <!-- Slide 20 -->
        <section>
          <h2>Slide 20: Key Points in History (Part 1)</h2>
          <ul>
            <li>Chief Complaint: nature &amp; onset of vision loss</li>
            <li>Pain: especially with eye movement</li>
            <li>Timeline: duration, progression</li>
            <li>Triggers: recent infection, vaccination, stress</li>
          </ul>
        </section>

        <!-- Slide 21 -->
        <section>
          <h2>Slide 21: Key Points in History (Part 2)</h2>
          <ul>
            <li>
              Systemic Review:
              <ul>
                <li>Neurological symptoms: numbness, weakness, ataxia</li>
                <li>Urinary incontinence, diplopia</li>
              </ul>
            </li>
            <li>
              Past Medical History:
              <ul>
                <li>Previous ON episodes</li>
                <li>Autoimmune or neurological disorders</li>
              </ul>
            </li>
            <li>Family History: MS, autoimmune diseases</li>
          </ul>
        </section>

        <!-- Slide 22 -->
        <section>
          <h2>Slide 22: Additional History Details</h2>
          <ul>
            <li>Medication Use: steroids, immunomodulators</li>
            <li>Social History: smoking, alcohol, occupation</li>
            <li>Travel History: consider infections</li>
            <li>Red Flags: systemic symptoms like fever, weight loss</li>
          </ul>
        </section>

        <!-- Slide 23 -->
        <section>
          <h2>Slide 23: Visual Acuity Testing</h2>
          <ul>
            <li>Snellen or ETDRS chart for best-corrected VA</li>
            <li>Record findings and compare with contralateral eye</li>
            <li>Check for pinhole improvement</li>
          </ul>
        </section>

        <!-- Slide 24 -->
        <section>
          <h2>Slide 24: Pupillary Examination</h2>
          <ul>
            <li>Check size, shape, symmetry</li>
            <li>Direct and consensual light reflex</li>
            <li>Swinging flashlight test (RAPD)</li>
            <li>Near reflex (accommodation, convergence)</li>
          </ul>
        </section>

        <!-- Slide 25 -->
        <section>
          <h2>Slide 25: Color Vision Testing</h2>
          <ul>
            <li>Ishihara plates</li>
            <li>Red desaturation test (compare intensity in each eye)</li>
            <li>Document severity or presence of color deficits</li>
          </ul>
        </section>

        <!-- Slide 26 -->
        <section>
          <h2>Slide 26: Visual Field Evaluation</h2>
          <ul>
            <li>Confrontation test (screening)</li>
            <li>Automated perimetry (Humphrey, etc.) for detailed mapping</li>
            <li>Identify scotomas or general field loss</li>
          </ul>
        </section>

        <!-- Slide 27 -->
        <section>
          <h2>Slide 27: Fundoscopic Examination</h2>
          <ul>
            <li>Acute ON: often normal disc (retrobulbar neuritis)</li>
            <li>Possible disc swelling (papillitis)</li>
            <li>Chronic: optic disc pallor (atrophy)</li>
          </ul>
        </section>

        <!-- Slide 28 -->
        <section>
          <h2>Slide 28: Neurological Examination</h2>
          <ul>
            <li>Cranial Nerves: check extraocular movements, CN V, etc.</li>
            <li>Motor Exam: weakness, spasticity</li>
            <li>Sensory Exam: pinprick, proprioception</li>
            <li>Coordination, Gait: look for ataxia or spastic gait</li>
          </ul>
        </section>

        <!-- Slide 29 -->
        <section>
          <h2>Slide 29: MRI of the Brain &amp; Orbits (Part 1)</h2>
          <ul>
            <li>
              <strong>Purpose</strong>: Identify CNS demyelinating lesions
            </li>
            <li>
              <strong>Optic Nerve Enhancement</strong>: T1 with gadolinium
              indicates inflammation
            </li>
            <li>
              <strong>T2/FLAIR Hyperintensities</strong>: Old or new MS plaques
            </li>
          </ul>
        </section>

        <!-- Slide 30 -->
        <section>
          <h2>Slide 30: MRI of the Brain &amp; Orbits (Part 2)</h2>
          <ul>
            <li>
              <strong>High-Risk for MS</strong>:
              <ul>
                <li>Multiple brain lesions</li>
                <li>Periventricular distribution</li>
              </ul>
            </li>
            <li>
              <strong>Optic Nerve Findings</strong>: Enhancement, swelling in
              acute phase
            </li>
          </ul>
        </section>

        <!-- Slide 31 -->
        <section>
          <h2>Slide 31: Visual Evoked Potentials (VEP)</h2>
          <ul>
            <li>
              Measures electrical conduction from retina to occipital cortex
            </li>
            <li>Prolonged P100 latency = demyelination</li>
            <li>Useful in detecting subclinical lesions</li>
          </ul>
        </section>

        <!-- Slide 32 -->
        <section>
          <h2>Slide 32: Optical Coherence Tomography (OCT)</h2>
          <ul>
            <li>Cross-sectional imaging of retinal nerve fiber layer (RNFL)</li>
            <li>Thinning of RNFL indicates axonal loss post-ON</li>
            <li>Useful to monitor progression or treatment response</li>
          </ul>
        </section>

        <!-- Slide 33 -->
        <section>
          <h2>Slide 33: Additional Laboratory Tests</h2>
          <ul>
            <li><strong>Serologic Tests</strong>: NMO-IgG, MOG-IgG</li>
            <li>
              <strong>Basic Labs</strong>: CBC, ESR, CRP, ANA (to exclude
              systemic causes)
            </li>
            <li>
              <strong>CSF Analysis</strong>: Oligoclonal bands supportive of MS
            </li>
          </ul>
        </section>

        <!-- Slide 34 -->
        <section>
          <h2>Slide 34: Major Differentials</h2>
          <ul>
            <li>Neuromyelitis Optica (NMO)</li>
            <li>MOG Antibody Disease</li>
            <li>Ischemic Optic Neuropathy</li>
            <li>Leber’s Hereditary Optic Neuropathy</li>
            <li>Infectious Optic Neuritis (syphilis, Lyme)</li>
            <li>Sarcoid/Autoimmune ON</li>
          </ul>
        </section>

        <!-- Slide 35 -->
        <section>
          <h2>Slide 35: Clues to Differentials</h2>
          <ul>
            <li>
              <strong>NMO</strong>: Severe, often bilateral, spinal cord lesions
            </li>
            <li>
              <strong>MOG-ON</strong>: Possible disc swelling, often good
              recovery
            </li>
            <li>
              <strong>Ischemic ON</strong>: Painless, altitudinal field loss,
              older pts
            </li>
            <li>
              <strong>Leber’s Hereditary</strong>: Gradual bilateral loss,
              maternal inheritance
            </li>
            <li>
              <strong>Infectious</strong>: Systemic signs, positive serologies
            </li>
          </ul>
        </section>

        <!-- Slide 36 -->
        <section>
          <h2>Slide 36: General Approach to Management</h2>
          <ul>
            <li>Confirm diagnosis: Clinical + MRI (+/- VEP)</li>
            <li>Assess MS risk: Brain MRI lesions</li>
            <li>Exclude atypical causes: NMO-IgG, MOG-IgG if indicated</li>
          </ul>
        </section>

        <!-- Slide 37 -->
        <section>
          <h2>Slide 37: High-Dose Corticosteroids</h2>
          <ul>
            <li>
              First-line for acute ON: IV methylprednisolone 1 g/day x 3–5 days
            </li>
            <li>Oral steroids can follow IV or be used in mild cases</li>
            <li>
              Speeds recovery but may not alter final visual outcome
              significantly
            </li>
          </ul>
        </section>

        <!-- Slide 38 -->
        <section>
          <h2>Slide 38: Disease-Modifying Therapies (DMTs) in MS</h2>
          <ul>
            <li>Indicated if MS or high risk of MS is diagnosed</li>
            <li>
              Examples:
              <ul>
                <li>Interferon β-1a/b</li>
                <li>Glatiramer acetate</li>
                <li>Dimethyl fumarate</li>
                <li>Natalizumab, Ocrelizumab, etc.</li>
              </ul>
            </li>
            <li>Reduce relapse rate &amp; slow progression</li>
          </ul>
        </section>

        <!-- Slide 39 -->
        <section>
          <h2>Slide 39: Other Immunomodulatory Therapies</h2>
          <ul>
            <li>
              <strong>NMO</strong>: Steroids + plasmapheresis; long-term:
              rituximab, etc.
            </li>
            <li>
              <strong>MOG-ON</strong>: Steroids, IVIG, or other
              immunosuppressants
            </li>
            <li>
              <strong>Goal</strong>: Address underlying autoimmune process
            </li>
          </ul>
        </section>

        <!-- Slide 40 -->
        <section>
          <h2>Slide 40: Plasma Exchange (Plasmapheresis)</h2>
          <ul>
            <li>Indication: Steroid-refractory acute ON</li>
            <li>Removes autoantibodies and immune complexes</li>
            <li>May improve vision in otherwise refractory cases</li>
          </ul>
        </section>

        <!-- Slide 41 -->
        <section>
          <h2>Slide 41: Symptomatic Management</h2>
          <ul>
            <li>Pain control: NSAIDs, acetaminophen</li>
            <li>Vision aids: large print, contrast enhancements</li>
            <li>Cooling strategies for Uhthoff’s phenomenon</li>
          </ul>
        </section>

        <!-- Slide 42 -->
        <section>
          <h2>Slide 42: Natural Course of ON</h2>
          <ul>
            <li>Partial recovery in 2–4 weeks, continues over months</li>
            <li>Good long-term visual prognosis in typical ON</li>
            <li>Mild residual defects possible (especially color vision)</li>
          </ul>
        </section>

        <!-- Slide 43 -->
        <section>
          <h2>Slide 43: Risk of Progression to MS</h2>
          <ul>
            <li>MRI lesion load correlates with higher risk</li>
            <li>
              Ongoing neurological exams &amp; repeat MRIs if new symptoms
            </li>
            <li>Early DMT may reduce or delay MS progression</li>
          </ul>
        </section>

        <!-- Slide 44 -->
        <section>
          <h2>Slide 44: Optic Neuritis Treatment Trial (ONTT)</h2>
          <ul>
            <li>Landmark trial comparing steroids vs. placebo</li>
            <li>
              IV steroids hastened recovery but no major long-term VA difference
            </li>
            <li>Oral steroids alone had higher short-term recurrence</li>
            <li>MRI lesions predicted higher MS risk</li>
          </ul>
        </section>

        <!-- Slide 45 -->
        <section>
          <h2>Slide 45: Pediatric Optic Neuritis</h2>
          <ul>
            <li>Often bilateral in children</li>
            <li>May follow viral infection or vaccination</li>
            <li>
              Treat with high-dose steroids, evaluate for underlying
              demyelination
            </li>
          </ul>
        </section>

        <!-- Slide 46 -->
        <section>
          <h2>Slide 46: Pregnancy and ON/MS</h2>
          <ul>
            <li>
              MS relapses may decrease during pregnancy, rebound postpartum
            </li>
            <li>DMT adjustments needed (some contraindicated in pregnancy)</li>
            <li>Steroids short-term generally safe if indicated</li>
          </ul>
        </section>

        <!-- Slide 47 -->
        <section>
          <h2>Slide 47: Emerging Therapies</h2>
          <ul>
            <li>
              Neuroprotective Agents: to protect axons during acute inflammation
            </li>
            <li>Remyelinating Therapies: promote myelin repair</li>
            <li>
              Biologics: advanced monoclonal antibodies targeting immune
              pathways
            </li>
          </ul>
        </section>

        <!-- Slide 48 -->
        <section>
          <h2>Slide 48: Patient Education &amp; Support</h2>
          <ul>
            <li>Explain ON &amp; MS link, disease course</li>
            <li>Lifestyle: avoid smoking, ensure Vitamin D, manage stress</li>
            <li>Resources: MS societies, vision rehab programs, counseling</li>
          </ul>
        </section>

        <!-- Slide 49 -->
        <section>
          <h2>Slide 49: Key Takeaways</h2>
          <ul>
            <li>
              ON: acute unilateral vision loss, eye pain, color desaturation
            </li>
            <li>Often first sign of MS; ~50% risk over 15 years</li>
            <li>Diagnosis: clinical exam (RAPD, color vision, VF), MRI, VEP</li>
            <li>
              Management: High-dose IV steroids, possible DMTs, good recovery
              typical
            </li>
          </ul>
        </section>

        <!-- Slide 50 -->
        <section>
          <h2>Slide 50: References</h2>
          <ul>
            <li>
              WebMD:
              <a
                href="https://www.webmd.com/multiple-sclerosis/optic-neuritis-ms-vision"
                target="_blank"
                >Optic Neuritis in MS</a
              >
            </li>
            <li>
              PubMed:
              <a
                href="https://pubmed.ncbi.nlm.nih.gov/12789593/"
                target="_blank"
                >Optic Neuritis &amp; MS (PMID 12789593)</a
              >
            </li>
            <li>Optic Neuritis Treatment Trial (ONTT) Publications</li>
            <li>National Multiple Sclerosis Society</li>
            <li>UpToDate: Optic Neuritis – Diagnosis &amp; Management</li>
          </ul>
          <p><strong>Thank You!</strong></p>
        </section>
      </div>
    </div>

    <!-- Reveal.js Scripts -->
    <script src="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/reveal.js"></script>
    <script>
      Reveal.initialize({
        hash: true, // Adds a URL hash so you can link to specific slides
        slideNumber: true, // Show slide number
        navigationMode: "linear",
        controls: true,
        progress: true,
        center: true,
      });
    </script>
  </body>
</html>
